Are you a Health Professional? Jump over to the doctors only platform. Click Here

Intranasal corticosteroid treatment appears beneficial for children with obstructive sleep apnoea

Print Friendly, PDF & Email

Using a fluticasone furoate nasal spray for treatment of obstructive sleep apnoea in children appears to reduce production of certain inflammatory cell proteins that may play a role in development of obstructive sleep apnoea, according to a report in the June issue of Archives of Otolaryngology—Head & Neck Surgery, one of the JAMA/Archives journals.

“Obstructive sleep apnoea syndrome is characterised by prolonged partial upper airway obstruction and/or intermittent complete obstruction with disruption of normal ventilation during sleep and normal sleep patterns,” the authors write as background information in the study. It is estimated that obstructive sleep apnoea syndrome (OSAS) occurs in 2 percent to 3 percent of children and can have a negative effect on overall quality of life. According to the authors, previous research has suggested a role for inflammation in OSAS, including increased release of certain cytokines and the presence of inflammatory cytokines.

To determine the effect of intranasal corticosteroid therapy on inflammatory cytokines (non-antibody proteins secreted by cells that act as mediators between cells) in adenoid tissues in children with OSAS, Rania Esteitie, M.D., and colleagues from The University of Chicago Medical Centre and Pritzker School of Medicine, conducted a randomised, prospective exploratory study of 24 children ages 2 to 12 years who were undergoing adenotonsillectomy (surgical removal of the tonsils and adenoids) for OSAS that had been documented by polysomnography.

Children were randomized into one of two groups: treatment (n=11) or no treatment (n=13). The 11 children in the treatment group received 55μg (microgram or mcg; equal to one millionth of a gram) of fluticasone furoate nasal spray (an intranasal corticosteroid) once daily for two weeks while the 13 children in the no-treatment group received no intranasal treatment. All children included in the analysis underwent adenotonsillectomy two weeks after initiation of treatment. The main outcome of the study was to determine the number of T-regulatory cells (specialised cells that act to suppress activation of the immune system) as well as levels of various cytokine receptors in both groups.

After the adenotonsillectomy, the authors weighed the removed adenoids from children in both groups to determine if treatment had worked to reduce the size of the tissue, but they found no significant difference in adenoid weight between the two groups.

The authors found that the treatment group had reduced levels of spontaneous IL-6 (a type I cytokine receptor that regulates cell growth and differentiation) production. The IL-6 cytokine is secreted by T-regulatory cells and induces cell growth differentiation in certain cells. The authors also note that it is an important predictor of cardiovascular risk and mortality. The treatment did not appear to have reduced levels of any other cytokine receptor examined, nor was there a significant difference in the number of T-regulatory cells produced in each group.

“In this study, we show reduction of IL-6, a proinflammatory cytokine, in adenoid tissue obtained from children with obstructive sleep apnoea syndrome treated with fluticasone furoate nasal spray,” the authors conclude. “This reduction could contribute to the clinical efficacy of this class of medications in the treatment of childhood obstructive sleep apnoea syndrome.”

(Source: JAMA/Archives: Archives of Otolaryngology—Head & Neck Surgery)

More information

For more information about sleep, including how much is good for you, tips for getting more sleep, and sleep disorders, as well as some useful videos, see


Print Friendly, PDF & Email


Posted On: 28 June, 2011
Modified On: 15 January, 2014


Created by: myVMC